La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Relmada Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Relmada Therapeutics..

Relmada Therapeutics (NASDAQ:RLMD) Azioni, Catena delle Opzioni

Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics Inc

Piper Sandler analyst Nathan Race maintains Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBCP#NASDAQ">IBCP</a>) with a Neutral and lowers the price target from $38 to $36.

News

Price Target

Analyst Ratings

IBCP

Piper Sandler Maintains Neutral on Independent Bank, Lowers Price Target to $36

AST SpaceMobile, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) announced on Monday it inked a Coordination Agreement with the U.S. National Science Foundation to implement best practices between satellite communications and ground-based optical, infrared and <a href="https://www.benzinga.com/pressreleases/25/04/b45036388/ast-spacemobile-and-u-s-national-science-foundation-establish-coordination-agreement-between-satel" target="_blank" rel="noreferrer noopener">radio astronomy observations</a>.
Under this deal, AST SpaceMobile commits to collaborate closely with NSF, its major facilities, and the broader U.S. astronomy community to mitigate any potential impact on ground-based astronomical facilities. 
These efforts will include adopting measures recommended by the International Astronomical Union&#8217;s Dark and Quiet Skies initiative, such as reducing satellite brightness and providing accurate, real-time satellite positioning data to observatories.
Also Read: <a href="https://www.benzinga.com/25/02/43985177/whats-going-on-with-ast-spacemobile-stock-wednesday" target="_blank" rel="noreferrer noopener">AST SpaceMobile Wins $43M U.S. Space Force Contract to Expand Satellite Communications</a>
AST SpaceMobile&#8217;s network aims to deliver cellular broadband connectivity directly from satellites to standard mobile phones, improving connectivity in underserved areas globally and eliminating dead zones. The network will bring millions of Americans into the digital economy and enable access to vital online services such as education, healthcare, banking, jobs and emergency response.
AST SpaceMobile&nbsp;reported&nbsp;<a target="_blank" href="https://www.benzinga.com/general/space/25/03/44095480/ast-spacemobile-stock-moves-higher-despite-q4-earnings-miss" rel="noreferrer noopener">fourth-quarter sales</a> of $1.92 million. The company reported a fourth-quarter adjusted loss of 18 cents per share, missing&nbsp;analyst estimates for a loss of 17 cents per share. AST SpaceMobile highlighted several achievements during the quarter, including new commercial agreements with Vodafone and the U.S. government, operational status for its first five BlueBird satellites, and accelerated manufacturing capabilities.
Elon Musk&#8217;s SpaceX <a href="https://www.benzinga.com/25/04/44731833/starlinks-challenges-poses-threat-to-the-high-valuation-of-elon-musks-spacex-report" target="_blank" rel="noreferrer noopener">has gained traction</a> with its satellite network, Starlink, but some experts, such as Tim Farrar, have questioned the sustainability of its current valuation, based significantly on the company&#8217;s success. In December, SpaceX valuation was $350 billion. The service&#8217;s inability to serve many internet customers in densely populated areas and high prices may limit its reach in rural regions and developing countries. Competing services, including Amazon.com Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) upcoming satellite constellation, Kuiper, pose another challenge.
ASTS Price Action: ASTS stock is down 1.47% at $23.41 at publication on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44111677/apple-partner-globalstar-teams-up-with-gct-semiconductor-to-power-satellite-messaging-with-iot-chips" target="_blank" rel="noreferrer noopener">Apple Partner Globalstar Teams Up With GCT Semiconductor to Power Satellite Messaging with IoT Chips</a></li>
</ul>
Photo: greenbutterfly via Shutterstock

SPACE

AMZN

ASTS

AST SpaceMobile Partners With US Science Foundation To Protect Astronomy Observations While Expanding Satellite Network

RBC Capital analyst Sabahat Khan maintains Aecon Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ARE#TSX">ARE</a>) with a Sector Perform and lowers the price target from C$18 to C$17.

TSX:ARE

RBC Capital Maintains Sector Perform on Aecon Group, Lowers Price Target to C$17

Piper Sandler analyst Matthew Clark maintains Heritage Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFWA#NASDAQ">HFWA</a>) with a Overweight and lowers the price target from $34 to $31.

HFWA

Piper Sandler Maintains Overweight on Heritage Financial, Lowers Price Target to $31

Citigroup analyst Paul Lejuez maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Neutral and lowers the price target from $8 to $6.

Citigroup Maintains Neutral on Under Armour, Lowers Price Target to $6

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/04/2025-04-28_08h37_21.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Risk To Nvidia</h4>
Please <a href="https://thearorareport.com/stock-market-chart-analysis-china-risk-to-nvidia-earnings-economic-data-nvda-mc-04282025">click here</a> for an enlarged chart of NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp; The chart of NVDA is being used to illustrate the point.&nbsp; NVDA is a very important stock for the overall market sentiment.</li>
<li>The chart shows NVDA stock dipped below Zone 4 on the trade war between the U.S. and China heating up.</li>
<li>The chart shows NVDA stock neared the bottom of our buy zone for a trade around position.  Trade around positions are a billionaire and hedge fund technique to maximize returns and minimize risks.  Please see the Trade Management Guidelines to read more.</li>
<li>The chart shows our signals to take partial profits on the trade around position on up spikes as NVDA stock rose to the top band of Zone 3.</li>
<li>The chart shows NVDA stock subsequently pulled back.</li>
<li>The chart shows NVDA stock is below Zone 3 as of this writing.</li>
<li>As full disclosure, the NVDA core position in our ZYX Buy Model Portfolio is long from $12.55.  Hedges were in place before the big drop.  After the drop, hedges became very profitable.  As full disclosure, we have given signals to take partial profits on hedges.</li>
<li>Dynamic hedging used by us is one of the keys to high risk adjusted returns.</li>
<li>There is a new challenge to Nvidia in AI chips from Huawei of China. In the early trade, the stock market is perceiving this as a risk for Nvidia.&nbsp; Huawei has a chip named Ascend 910D.&nbsp; This chip is reportedly more powerful than Nvidia's H100 chip. Several Chinese companies are reportedly about to start testing this new chip.</li>
<li>Huawei is already on track to ship about 8000 of the prior Ascend 910B and 910C chips.</li>
<li>In our analysis, there is no immediate negative impact for Nvidia.  Here are the reasons:
<ul>
<li>The Trump administration has already restricted Nvidia from selling advanced AI chips to China.</li>
<li>Nvidia is already de-risked by taking a write off of over $5B for chips manufactured for China that can no longer be shipped to China because of current regulations.</li>
<li>Huawei is still far behind Nvidia.&nbsp; Investors need to be aware that over a period of time Huawei may catch up to Nvidia.</li>
</ul>
</li>
<li>On the positive side, the stock market is expecting several trade deal announcements this week including potential deals with India, Japan, South Korea, and Australia.</li>
<li>This week brings fresh economic data:
<ul>
<li>JOLTS job openings and consumer confidence will be released tomorrow at 10am ET.</li>
<li>ADP, the largest private payroll processor, will give its glimpse into the jobs picture on Wednesday at 8:15am ET.</li>
<li>Personal income and spending, Q1 Advanced GDP and GDP Deflator, as well as PCE, the Fed's favorite inflation gauge, will be released Wednesday at 8:30am ET.</li>
<li>Initial jobless claims and ISM Manufacturing Index will be released Thursday at 8:30am ET.</li>
<li>The mother of all reports, the jobs report, will be released Friday at 8:30am ET.</li>
</ul>
</li>
<li>A flood of earnings will be reported this week, including earnings from NXP Semiconductors N.V. (NXPI), PayPal Holdings, Inc. (PYPL), Pfizer Inc. (PFE), SoFi Technologies, Inc. (SOFI), Caesars Entertainment, Inc. (CZR), Mondelez International, Inc. (MDLZ), Qorvo, Inc. (QRVO), Snap Inc. ( SNAP), Starbucks Corporation ( SBUX), Visa Inc. (V), Caterpillar Inc. (CAT), Meta Platforms, Inc. (META), Microsoft Corporation (MSFT), MGM Resorts International (MGM), Qualcomm Inc. (QCOM), Eli Lilly and Company (LLY), McDonald&#8217;s Corporation (MCD), Amazon.com, Inc. (AMZN), and Apple Inc. (AAPL).</li>
<li>In our analysis, expectations from earnings are high.  In totality, there is about a 70% probability that the companies will report earnings better than consensus.  </li>
<li>For the AI trade, especially important from earnings will be capital spend numbers from Meta Platforms Inc (META), Microsoft Corp (MSFT), and Amazon.com, Inc. (AMZN).  META is expected to stay steadfast.  There have been several rumors of AMZN and MSFT pulling back.  </li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Amazon (AMZN), Microsoft (MSFT), Alphabet Inc Class C (GOOG), Meta (META), Tesla Inc (TSLA), and Apple (AAPL).
In the early trade, money flows are negative in Nvidia (NVDA).
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust (SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is seeing buying.
<h4 class="wp-block-heading">Arora Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.  Our proprietary Protection Band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Equities

Market Summary

Politics

Econ #s

Opinion

Trading Ideas

$BTC

NVDA

China Risk To Nvidia, Flood Of Earnings And Jobs Report Ahead

Piper Sandler analyst Nathan Race maintains Horizon Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBNC#NASDAQ">HBNC</a>) with a Neutral and lowers the price target from $18 to $17.

HBNC

Piper Sandler Maintains Neutral on Horizon Bancorp, Lowers Price Target to $17

Citigroup analyst Paul Lejuez maintains Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Neutral and lowers the price target from $72 to $57.

Citigroup Maintains Neutral on Nike, Lowers Price Target to $57

An Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) analyst says results will be "better-than-feared" when the technology giant reports second-quarter<a href="https://www.benzinga.com/earnings"> financial results Thursday.</a>
The Apple Analyst: JPMorgan analyst Samik Chatterjee maintained an Overweight rating on Apple with a $245 price target.
The Analyst Takeaways: Chatterjee said in a new investor note that fears of demand disruption and cost headwinds from tariffs on China could weigh on Apple stock ahead of quarterly earnings.
Read Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44961882/iphone-resecue-apple-tariff-worries"> Apple Stock Can Brush Off Tariff Concerns, Analyst Says Q2 Beat Coming Thanks To iPhone Demand</a>
"We are positive on AAPL shares with a near-term view into a positive set up into earnings with the likelihood of better-than-feared outcomes in relation to both revenues and gross margins," Chatterjee said.
The analyst expects "modest pull-forward" in demand thanks to consumer upgrades and channel inventory fill.
Chatterjee said revenue will likely be stronger than expected in the second quarter, and momentum could carry over into the third quarter. 
Expect Apple to guide to low-single to mid-single-digit revenue growth for the third quarter, he said. The analyst sees lower downside risk for the full financial year than investors expect. Tariffs remain a "significant uncertainty," but Apple's history could overcome the weakness.
"The resilience of revenue and earnings estimates as well as a proven track record of earnings protection in downturns remains key to investors still looking at AAPL shares favorably despite the uncertainty."
Chatterjee said the company's earnings and guidance could show Apple's resilience in the face of tariff worries and the macro environment.
Services growth, AI opportunities and the new iPhone 17 cycle are catalysts that provide "limited downside risks over the medium term," Chatterjee said.
AAPL Price Action: Apple stock is down 0.6% to $207.96 on Monday versus a 52-week trading range of $169.11 to $260.09. Apple stock is down 14.7% year-to-date in 2025, while shares remain up 19.9% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44366890/apple-stock-faces-pressure-from-declining-iphone-revenue-could-companys-first-foldable-smartphone-in-2026-reverse-course">Apple Stock Faces Pressure From Declining iPhone Revenue: Could Company&#8217;s First Foldable Smartphone In 2026 Reverse Course?</a></li>
</ul>
Image: Shutterstock

Analyst Color

Previews

Reiteration

Tech

AAPL

Apple Q2 Will Be 'Better-Than-Feared': Analyst Says iPhone Company Has 'Proven Track Record'

WIIM

MYNZ

Mainz Biomed shares are trading higher after the company announced its Q1 corporate update and path to FDA premarket approval.

Piper Sandler analyst Nathan Race maintains First Merchants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRME#NASDAQ">FRME</a>) with a Overweight and lowers the price target from $55 to $49.

FRME

Piper Sandler Maintains Overweight on First Merchants, Lowers Price Target to $49

Piper Sandler analyst Nathan Race maintains First Business Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIZ#NASDAQ">FBIZ</a>) with a Overweight and raises the price target from $57 to $58.

FBIZ

Piper Sandler Maintains Overweight on First Business Finl Servs, Raises Price Target to $58

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 200 points on Monday.
The Dow traded down 0.27% to 40,004.11 while the NASDAQ fell 1.19% to 17,175.43. The S&amp;P 500 also fell, dropping, 0.72% to 5,485.36.
Check This Out: <a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a>
Leading and Lagging Sectors Financial shares jumped by 0.6% on Monday.
In trading on Monday, information technology fell by 0.6%.
Top Headline
Roper Technologies, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) reported better-than-expected earnings for its first quarter and raised its forecast.
The company posted first-quarter adjusted earnings per share of $4.78, beating the street view of $4.74. Quarterly sales of $1.88 billion outpaced the analyst consensus estimate of $1.82 billion.
Roper Technologies expects fiscal 2025 adjusted earnings per share of $19.80-$20.05 (compared to a previous outlook of $19.75-$20.00), versus the $19.92 estimate. It increased its full-year total revenue growth outlook to ~12% or $7.88 billion (compared to a previous outlook of 10%+ or $7.74 billion) and an analyst estimate of $7.74 billion. It reiterated organic revenue growth of +6-7%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Galmed Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLMD#NASDAQ">GLMD</a>) shares shot up 46% to $2.2999. Galmed signed a term sheet for the development of novel semaglutide sublingual formulation.</li>
<li>Shares of CG Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>)got a boost, surging 31% to $29.21 after the company announced that cretostimogene grenadenorepvec monotherapy data was presented at the American Urological Association Annual Meeting.</li>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares were also up, gaining 42% to $1.15 after the company signed a secured credit facility with Yorkville Advisors. The company also reported preliminary first-quarter results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares dropped 28% to $0.0935 after the company announced it approved a plan to implement a workforce reduction.</li>
<li>Shares of Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) were down 15% to $16.86.</li>
<li>Protara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) was down, falling 19% to $3.4899 as the company announced interim results highlighting durable clinical responses with TARA-002 In high-risk NMIBC.</li>
</ul>
Commodities In commodity news, oil traded down 2% to $61.78 while gold traded up 0.6% at $3,316.80.
Silver traded down 0.5% to $32.845 on Monday, while copper rose 0.1% to $4.90.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.74%, Germany's DAX 40 gained 0.67% and France's CAC 40 gained 0.87%. Spain's IBEX 35 Index gained 0.81%, while London's FTSE 100 rose 0.30%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 surging 0.38%, China's Shanghai Composite falling 0.20%, Hong Kong's Hang Seng Index falling 0.04% and India's BSE Sensex gaining 1.27%.
Economics
The Dallas Fed manufacturing index will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45037469/stride-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday">Stride To Rally Around 10%? Here Are 10 Top Analyst Forecasts For</a> Monday.</li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

Markets

CGON

GLMD

GRPN

PLUG

SPRB

TARA

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook

Piper Sandler analyst Justin Crowley maintains Eagle Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGBN#NASDAQ">EGBN</a>) with a Neutral and lowers the price target from $25 to $21.

EGBN

Piper Sandler Maintains Neutral on Eagle Bancorp, Lowers Price Target to $21

Piper Sandler analyst Matthew Clark maintains CVB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVBF#NASDAQ">CVBF</a>) with a Overweight and lowers the price target from $25 to $24.

CVBF

Piper Sandler Maintains Overweight on CVB Financial, Lowers Price Target to $24

Piper Sandler analyst Matthew Clark maintains Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) with a Overweight and lowers the price target from $32 to $30.

COLB

Piper Sandler Maintains Overweight on Columbia Banking System, Lowers Price Target to $30

Protara Therapeutics shares are trading lower. The company announced updated results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002

Citigroup analyst Paul Lejuez maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Neutral and lowers the price target from $330 to $275.

LULU

Citigroup Maintains Neutral on Lululemon Athletica, Lowers Price Target to $275

Piper Sandler analyst Justin Crowley maintains Civista Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIVB#NASDAQ">CIVB</a>) with a Neutral and raises the price target from $23 to $24.

CIVB

Piper Sandler Maintains Neutral on Civista Bancshares, Raises Price Target to $24

Citigroup analyst Paul Lejuez maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Buy and lowers the price target from $215 to $150.

DECK

Citigroup Maintains Buy on Deckers Outdoor, Lowers Price Target to $150

Health Care

Press Releases

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Comments

Relmada Therapeutics

Relmada Therapeutics (RLMD) Opzioni

Relmada Therapeutics (NASDAQ:RLMD) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO